본문으로 건너뛰기
← 뒤로

Primary Pulmonary Non-Hodgkin Lymphoma: A Report of Two Cases and a Review of the Literature Emphasizing the Role of Radiotherapy.

Cureus 2026 Vol.18(3) p. e104621

Fahmy V, Huynh A, Block AM, Welsh J

📝 환자 설명용 한 줄

Primary pulmonary non-Hodgkin lymphoma (PPL) is a rare malignancy most commonly presented as indolent marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) or bronchus-associated l

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • 연구 설계 cross-sectional

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Fahmy V, Huynh A, et al. (2026). Primary Pulmonary Non-Hodgkin Lymphoma: A Report of Two Cases and a Review of the Literature Emphasizing the Role of Radiotherapy.. Cureus, 18(3), e104621. https://doi.org/10.7759/cureus.104621
MLA Fahmy V, et al.. "Primary Pulmonary Non-Hodgkin Lymphoma: A Report of Two Cases and a Review of the Literature Emphasizing the Role of Radiotherapy.." Cureus, vol. 18, no. 3, 2026, pp. e104621.
PMID 41939553

Abstract

Primary pulmonary non-Hodgkin lymphoma (PPL) is a rare malignancy most commonly presented as indolent marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) or bronchus-associated lymphoid tissue (BALT). Aggressive subtypes of PPL, such as diffuse large B-cell lymphoma (DLBCL), occur less frequently. Diagnosis and workup require tissue biopsy, immunophenotyping, and cross-sectional imaging, often supplemented by positron emission tomography (PET)/computed tomography (CT) for staging and treatment planning. Radiation therapy or radiotherapy (RT) is a cornerstone in managing localized, indolent PPL, offering durable local control with minimal toxicity. Modern involved-site RT (ISRT) techniques deliver radiation in conventional fractionation schedules, precisely targeting pulmonary lesions while sparing surrounding lung and mediastinal structures. RT can be used alone for early-stage disease or following systemic therapy for residual or refractory lesions. The cases in this report highlight the importance of histology-driven, individualized treatment planning and the pivotal role of RT in achieving optimal outcomes in this rare malignancy.